Neurodevelopmental Drug Development Summit

As investment in rare neurodevelopmental disorders is surging, there has never been a better time to unite all the key stakeholders across this fast-evolving community.

The inaugural Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups paving the way towards symptomatic and successful disease modifying treatments.

Developing new outcome measures that measure incremental change and target the neurodevelopmental disease itself, driving design innovation across disease-specific clinical trials, and capitalizing on the advances in new therapeutic modalities to drastically change the lives of patients in need.

With increased understanding of genetic mechanisms sharpening our thoughts on targets and disease modifying approaches, we are now closer than ever to discovering treatments for the highest unmet need across neurodevelopmental disorders.

If you are working towards treatments for rare neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome, or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.

Speakers: Allyson Berent Chief Operating Officer | FAST GeneTx | Biotherapeutics Chief Scientific Officer, Anish Bhatnagar Chief Executive Officer Soleno Therapeutics, Audrey Thurm Director, Neurodevelopmental and Behavioral Phenotyping Service, Office of the Clinical Director National Institute of Mental Health, NIH, Barbara Bailus Assistant Professor of Genetics Keck Graduate Institute, Brian Ranes Principal Investigator, Imaging Core Amicus Therapeutics, Charlene Son Rigby CEO | President and Founding Board Member RARE-X | STXBP1 Foundation, Charles Large Chief Executive Officer Autifony Therapeutics, Chrisopher U Missling President and CEO Anavex Life Sciences, Elizabeth M. Berry-Kravis Professor, Co-director, Molecular Diagnostics Section of the Genetic Laboratory | Director Fragile X Clinic and Research Program; Co- Director Rush University Medical Center | Angelman Syndrome Clinic and Research Program, Greg Dillon Senior Scientist Biogen, Jennifer Panagoulias Senior Regulatory Advisor GeneTx Biotherapeutics, Jeremy Levin CEO and Chairman Ovid Therapeutics, John Kealy Principal Scientist, Academic Liaison Manager Ulysses Neuroscience, Katie Clapp President and Co- Founder FRAXA, Kevin Pelphrey Harrison-Wood Professor University of Virginia, Kimberly Parkerson Senior Medical Director Stoke Therapeutics, Luke Rosen Head of Accelerated Development and Community Engagement Ovid Therapeutics, Lynn Durham CEO and Founder STALICLA, Massimiliano Bianchi Founder, President and CEO Ulysses Neuroscience, Michela Fagiolini Associate in Neurology, Associate Professor of Neurology Harvard Medical School, Mustafa Sahin Director, Translational Neuroscience Center; Director, Translational Research Program; Rosamund Stone Zander Chair, Professor of Neurology Harvard Medical School, Pam Ventola Associate Professor Yale Child Study Center, PJ Brookes Program Director, Office of Rare Diseases Research National Center for Advancing Translational Sciences, National Institutes of Health, Randall Carpenter Co-Founder | CMO Allos Pharma | Rett Syndrome Research Trust, Robert Komorowski Senior Clinical Scientist Biogen, Robert Ring Chief Executive Officer Kaerus Bioscience, Samir Koirala Director of Research, Genetic and Neurodevelopmental Disorders Unit Biogen, Sharyl Fyffe-Maricich Executive Director, Molecular and Cell Biology, Research Ultragenyx, Steven Gray Associate Professor University of Texas Southwestern Medical Center, Theresa Strong Director of Research Programs Foundation for Prader- Willi Research (FPWR), Yael Weiss Vice President Business Development Ultragenyx

Others Details

Brochure: https://go.evvnt.com/867375-3?pid=6581